The aim of the current analysis is to compare outcomes in patients with CP-CML who started on a daily dose of 45 mg ponatinib in PACE, which did not have a response-based dosing strategy, and in OPTIC, which included prospective dose reductions after patients reached a response of ≤1% BCR::ABL1IS. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.